Scalable and Interoperable framework for a clinically diverse and generalizable sepsis Biorepository using Electronic alerts for Recruitment driven by Artificial Intelligence (short title: SIBER-AI)

使用人工智能驱动的招募电子警报的临床多样化和通用脓毒症生物库的可扩展和可互操作框架（简称：SIBER-AI）

• 批准号: 10576015
• 负责人: ANNETTE M. ESPER
• 金额: $ 18.32万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10576015
• 关键词: Accident and Emergency department; Acute; Algorithms; Ambulances; Animal Model; Antibiotics; Artificial Intelligence; Biological; Cause of Death; Cells; Cessation of life; Characteristics; Clinical; Clinical Research; Collection; Conceptions; Consent; Critical Care; Critical Illness; Cryopreserved Cell; Decision Making; Development; Diagnosis; Disease; Disparity; Early treatment; Electronics; Enrollment; Environment; Ethics; Family; Functional disorder; Health; Hospital Mortality; Hospitals; Hour; Human; Immune response; Individual; Infection; Informed Consent; Integration Host Factors; Intensive Care Units; Intervention; Learning; Length of Stay; Maintenance; Managed Care; Measures; Methods; Modeling; Organ; Outcome; Patient Admission; Patient-Focused Outcomes; Patients; Phenotype; Physiological; Population; Population Heterogeneity; Procedures; Process; Research; Research Personnel; Research Support; Resources; Risk; Sepsis; Severities; Site; Source; Specimen; Standardization; Suspensions; Testing; Time; Trust; United States; Variant; Volatilization; acute care; biobank; cell type; clinical translation; cohort; design; experience; gender disparity; hospital care; improved; improved outcome; interoperability; mortality; mortality risk; multimodality; multiple omics; novel; novel strategies; operation; patient population; personalized management; precision medicine; preservation; racial disparity; recruit; repository; screening; septic patients; surrogate decision maker; targeted treatment; treatment and outcome; ward; wearable sensor technology

PROJECT SUMMARY Sepsis is a major health challenge worldwide that is associated with a significant risk of mortality. The key to improved outcomes in sepsis is earlier treatment once diagnosed, with delays in therapy being associated with worse outcomes. Sepsis is a heterogenous disease, and thus despite decades of research focused on various aspects of sepsis, there still remains much to be learned about the underlying mechanisms that result in differences in outcomes. The utilization of biorepositories gives investigators the opportunity to study different mechanisms of disease; however, it is imperative that we collect biospecimens early on in disease and at different time point in order to understand disease trajectory. Furthermore, there are opportunities within critical care research to diversify the patient population enrolled in studies in order to investigate disparities that occur in sepsis. Thus, the need to develop best practices and standard operation procedures are required that may serve as templates for establishing scalable and generalizable sepsis biorepositories. This proposal aims to 1) develop an integrated multi-modal clinical, physiologic, volatilomic, and multi-omic biorepository profile driven by a semi-autonomous screening algorithm to enrich sepsis phenotypes; 2)design and test novel methods of biospecimen collection among enriched sepsis populations in both ambulance and acute care hospital environments ; and 3)develop novel approaches to biorepository consent that match the clinical context of sepsis, maximize representativeness among patients, and enhance trust and engagement among patients and surrogate decision-makers.

项目总结 脓毒症是世界范围内的一个重大健康挑战，与巨大的死亡风险有关。解决问题的关键 脓毒症预后的改善是在确诊后及早治疗，延迟治疗与 更糟糕的结果。脓毒症是一种异质性疾病，因此尽管几十年的研究集中在各种 在脓毒症的各个方面，仍然有许多关于导致 结果上的差异。生物信息库的利用使研究人员有机会研究不同的 疾病的机制；然而，我们必须在疾病早期和在 不同的时间点，以了解疾病的轨迹。此外，内部也有机会 重症监护研究，以使参加研究的患者群体多样化，以调查 发生在败血症中。因此，需要制定最佳做法和标准作业程序。 这可以作为建立可扩展和可推广的脓毒症生物信息库的模板。这项建议 目标是1)开发集成的多模式临床、生理、挥发和多组生物信息库 由半自主筛选算法驱动的配置文件以丰富脓毒症表型；2)设计和测试新颖 急救车和急救中浓缩脓毒症人群中生物样品的采集方法 医院环境；以及3)开发与临床相匹配的生物信息库同意的新方法 脓毒症的背景，最大限度地提高患者的代表性，并增强患者之间的信任和参与度 病人和代孕决策者。